跳转至内容
Merck
CN

SML3042

Sigma-Aldrich

iP300

≥97% (HPLC)

别名:

2-(3′-Fluoro-5′-(1-(2-(methylamino)-2-oxoethyl)-1H-pyrazol-4-yl)-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-indene]-1-yl)-N-(4-fluorobenzyl)-N-(1,1,1-trifluoropropan-2-yl)acetamide, 3-Fluoro-N-[(4-fluorophenyl)methyl]-2,3-dihydro-5-[1-[2-(methylamino)-2-oxoethyl]-1H-pyrazol-4-yl]-2,5-dioxo-N-(2,2,2-trifluoro-1-methylethyl)spiro[imidazolidine-4,1-[1H]indene]-1-acetamide, N-(4-fluorobenzyl)-2-(3-fluoro-5-{1-[2-(methylamino)-2-oxoethyl]-1H-pyrazol-4-yl}-2,5-dioxo-2,3-dihydro-1H-spiro[imidazolidine-4,1-inden]-1-yl)-N-(1,1,1-trifluoropropan-2-yl)acetamide, iP300v/w, iP300w and iP300v mix, iP300w/v

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C29H27F5N6O4
分子量:
618.55
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥97% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

O=C(NC1(C2=O)CC(C3=C1C=CC(C4=CN(N=C4)CC(NC)=O)=C3)F)N2CC(N(CC5=CC=C(C=C5)F)C(C(F)(F)F)C)=O

InChI

1S/C29H27F5N6O4/c1-16(29(32,33)34)39(12-17-3-6-20(30)7-4-17)25(42)15-40-26(43)28(37-27(40)44)10-23(31)21-9-18(5-8-22(21)28)19-11-36-38(13-19)14-24(41)35-2/h3-9,11,13,16,23H,10,12,14-15H2,1-2H3,(H,35,41)(H,37,44)

InChI key

SWXCHCQCWFXILM-UHFFFAOYSA-N

生化/生理作用

Potent histone acetyltransferase p300/CBP inhibitor that prevents DUX4-induced cytotoxicity and transcription activity in vitro and in vivo.
iP300, a mixture of 8 diastereomers, is a potent histone acetyltransferase (HAT) p300/CBP inhibitor (p300 IC50 = 33 nM by H3K9Ac HTRF assay). An active diastereomer(s)-enriched pool (iP300w) obtained by partial HPLC separation prevents DUX4-induced cytotoxicity and transcription activity in human myoblast LHCN-M2 cultures (0.1-1 μM) and shows in vivo efficacy against muscle loss (0.3 mg/kg/day i.p.) in a murine model of facioscapulohumeral muscular dystrophy (FSHD).

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Darko Bosnakovski et al.
Science advances, 5(9), eaaw7781-eaaw7781 (2019-09-20)
Facioscapulohumeral muscular dystrophy (FSHD) results from mutations causing overexpression of the transcription factor, DUX4, which interacts with the histone acetyltransferases, EP300 and CBP. We describe the activity of a new spirocyclic EP300/CBP inhibitor, iP300w, which inhibits the cytotoxicity of the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门